# Trastuzumab Emtansine

## Kadcyla inj 100mg

| TAH Drug Code      | [IKAD1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IKAD1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast Cancer Metastatic Breast Cancer Monotherapy for the treatment of HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane， either separately or in combination. Eligible patients must meet one of the following criteria: - Have received prior therapy for metastatic disease， or - Experienced cancer recurrence during neoadjuvant/adjuvant therapy or within 6 months after completing treatment. Early Breast Cancer Monotherapy for the adjuvant treatment of HER2-positive early breast cancer in patients with residual invasive disease after receiving neoadjuvant therapy based on taxane and trastuzumab.                                             |
| Dosing             | 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever， chills， or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Specific contraindications have not been determined.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common: Constipation (17-27%)， Nausea (40-42%)， Hemorrhage， All Grades (29-32%)， Thrombocytopenia， All Grades (29-31%)， Increased liver enzymes， All Grades (29-32%)， Musculoskeletal pain (30-36%)， Headache (28%)， Fatigue (36%) Serious: Heart failure， Left ventricular cardiac dysfunction (1.8-3%)， Injection site extravasation， Anemia， Grade 3 or 4 (1.1-4.1%)， Hemorrhage， Grade 3 or 4 (0.4-1.8%)， Thrombocytopenia， Grade 3 or 4 (6-15%)， Hepatotoxicity， Increased liver enzymes， Grade 3 or 4 (1.5-8%)， Injury of liver， Liver regeneration (0.3-0.4%)， Non-allergic anaphylaxis， Dyspnea (8-12%)， Interstitial lung disease， Pneumonitis (1.1-1.2%)                               |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/trastuzumab-emtansine-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

## KADCYLA inj 160mg

| TAH Drug Code      | [IKAD6](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IKAD6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast Cancer Metastatic Breast Cancer Monotherapy for the treatment of HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane， either separately or in combination. Eligible patients must meet one of the following criteria: - Have received prior therapy for metastatic disease， or - Experienced cancer recurrence during neoadjuvant/adjuvant therapy or within 6 months after completing treatment. Early Breast Cancer Monotherapy for the adjuvant treatment of HER2-positive early breast cancer in patients with residual invasive disease after receiving neoadjuvant therapy based on taxane and trastuzumab.                                             |
| Dosing             | 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever， chills， or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Specific contraindications have not been determined.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common: Constipation (17-27%)， Nausea (40-42%)， Hemorrhage， All Grades (29-32%)， Thrombocytopenia， All Grades (29-31%)， Increased liver enzymes， All Grades (29-32%)， Musculoskeletal pain (30-36%)， Headache (28%)， Fatigue (36%) Serious: Heart failure， Left ventricular cardiac dysfunction (1.8-3%)， Injection site extravasation， Anemia， Grade 3 or 4 (1.1-4.1%)， Hemorrhage， Grade 3 or 4 (0.4-1.8%)， Thrombocytopenia， Grade 3 or 4 (6-15%)， Hepatotoxicity， Increased liver enzymes， Grade 3 or 4 (1.5-8%)， Injury of liver， Liver regeneration (0.3-0.4%)， Non-allergic anaphylaxis， Dyspnea (8-12%)， Interstitial lung disease， Pneumonitis (1.1-1.2%)                               |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/trastuzumab-emtansine-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

